Integrating Novel Therapeutic Monoclonal Antibodies Into the Management of Head and Neck Cancer

被引：45

作者：

Bauman, Julie E. ^{[1
]}

Ferris, Robert L. ^{[2
,3
,4
]}

机构：

[1] Univ Pittsburgh Canc Inst, Dept Internal Med, Div Hematol Oncol, Pittsburgh, PA 15232 USA

[2] Univ Pittsburgh Canc Inst, Dept Otolaryngol, Pittsburgh, PA 15232 USA

[3] Univ Pittsburgh Canc Inst, Dept Immunol, Pittsburgh, PA 15232 USA

[4] Univ Pittsburgh Canc Inst, Canc Immunol Program, Pittsburgh, PA 15232 USA

来源：

CANCER | 2014年 / 120卷 / 05期

基金：

美国国家卫生研究院;

关键词：

SQUAMOUS-CELL CARCINOMA; ANTIGEN-PROCESSING MACHINERY; CHEMOTHERAPY PLUS CETUXIMAB; FACTOR RECEPTOR EXPRESSION; HPV-ASSOCIATED HEAD; REGULATORY T-CELLS; NATURAL-KILLER; HUMAN-PAPILLOMAVIRUS; IN-VIVO; ANTITUMOR-ACTIVITY;

D O I：

10.1002/cncr.28380

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Head and neck squamous cell carcinoma (HNSCC) is an immunosuppressive malignancy. Interest in developing novel immunotherapies in HNSCC has been reawakened by the success of cetuximab, a therapeutic monoclonal antibody (mAb) against the epidermal growth factor receptor, which likely relies on immune as well as antisignaling mechanisms. This review focuses on novel therapeutic mAbs in current clinical development against established mechanisms of immune evasion in HNSCC, targeting: 1) tumor antigens, with resultant potential to induce antibody-dependent cell-mediated cytotoxicity and T cell activation; 2) immunosuppressive cytokines; 3) costimulatory tumor necrosis factor-family receptors; and 4) coinhibitory immune checkpoint receptors. Clinical trials of immunotherapeutic mAbs as monotherapy, in combination with cytolytic standard therapies exposing tumor antigens or in combination with other immunomodulatory mAbs, are urgently needed in HNSCC. © 2013 American Cancer Society.

引用

页码：624 / 632

页数：9

共 100 条

[1] Antitumor activity of human papillomavirus type 16 E7-specific T cells against virally infected squamous cell carcinoma of the head and neck [J].

Albers, A ;

Abe, K ;

Hunt, J ;

Wang, J ;

Lopez-Albaitero, A ;

Schaefer, C ;

Gooding, W ;

Whiteside, TL ;

Ferrone, S ;

DeLeo, A ;

Ferris, RL .

CANCER RESEARCH, 2005, 65 (23) :11146-11155

[2] Immune responses to p53 in patients with cancer:enrichment in tetramer+p53 peptide-specific T cells and regulatory T cells at tumor sites [J].

Albers, AE ;

Ferris, RL ;

Kim, GG ;

Chikamatsu, K ;

DeLeo, AB ;

Whiteside, TL .

CANCER IMMUNOLOGY IMMUNOTHERAPY, 2005, 54 (11) :1072-1081

[3] Nuclear factor-κB-related serum factors as longitudinal biomarkers of response and survival in advanced oropharyngeal carcinoma [J].

Allen, Clint ;

Duffy, Sonia ;

Teknos, Theodoros ;

Islam, Mozaffarul ;

Chen, Zhong ;

Albert, Paul S. ;

Wolf, Gregory ;

Van Wales, Carter .

CLINICAL CANCER RESEARCH, 2007, 13 (11) :3182-3190

[4]

Ang KK, 2002, CANCER RES, V62, P7350

[5] Cetuximab and bevacizumab: preclinical data and phase II trial in recurrent or metastatic squamous cell carcinoma of the head and neck [J].

Argiris, A. ;

Kotsakis, A. P. ;

Hoang, T. ;

Worden, F. P. ;

Savvides, P. ;

Gibson, M. K. ;

Gyanchandani, R. ;

Blumenschein, G. R., Jr. ;

Chen, H. X. ;

Grandis, J. R. ;

Harari, P. M. ;

Kies, M. S. ;

Kim, S. .

ANNALS OF ONCOLOGY, 2013, 24 (01) :220-225

[6] Phase III Randomized, Placebo-Controlled Trial of Docetaxel With or Without Gefitinib in Recurrent or Metastatic Head and Neck Cancer: An Eastern Cooperative Oncology Group Trial [J].

Argiris, Athanassios ;

Ghebremichael, Musie ;

Gilbert, Jill ;

Lee, Ju-Whei ;

Sachidanandam, Kamakshi ;

Kolesar, Jill M. ;

Burtness, Barbara ;

Forastiere, Arlene A. .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (11) :1405-1414

[7] PD-1-Expressing Tumor-Infiltrating T Cells Are a Favorable Prognostic Biomarker in HPV-Associated Head and Neck Cancer [J].

Badoual, Cecile ;

Hans, Stephane ;

Merillon, Nathalie ;

Van Ryswick, Cordelia ;

Ravel, Patrice ;

Benhamouda, Nadine ;

Levionnois, Emeline ;

Nizard, Mevyn ;

Si-Mohamed, Ali ;

Besnier, Nicolas ;

Gey, Alain ;

Rotem-Yehudar, Rinat ;

Pere, Helene ;

Tran, Thi ;

Guerin, Coralie L. ;

Chauvat, Anne ;

Dransart, Estelle ;

Alanio, Cecile ;

Albert, Sebastien ;

Barry, Beatrix ;

Sandoval, Federico ;

Quintin-Colonna, Francoise ;

Bruneval, Patrick ;

Fridman, Wolf H. ;

Lemoine, Francois M. ;

Oudard, Stephane ;

Johannes, Ludger ;

Olive, Daniel ;

Brasnu, Daniel ;

Tartour, Eric .

CANCER RESEARCH, 2013, 73 (01) :128-138

[8] Decreased levels of alternative co-stimulatory receptors OX40 and 4-1BB characterise T cells from head and neck cancer patients [J].

Baruah, Paramita ;

Lee, Michael ;

Odutoye, Tunde ;

Williamson, Peter ;

Hyde, Nicholas ;

Kaski, Juan Carlos ;

Dumitriu, Ingrid E. .

IMMUNOBIOLOGY, 2012, 217 (07) :669-675

[9] Preferential apoptosis of CD56dim natural killer cell subset in patients with cancer [J].

Bauernhofer, T ;

Kuss, I ;

Henderson, B ;

Baum, AS ;

Whiteside, TL .

EUROPEAN JOURNAL OF IMMUNOLOGY, 2003, 33 (01) :119-124

[10] CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans [J].

Beatty, Gregory L. ;

Chiorean, Elena G. ;

Fishman, Matthew P. ;

Saboury, Babak ;

Teitelbaum, Ursina R. ;

Sun, Weijing ;

Huhn, Richard D. ;

Song, Wenru ;

Li, Dongguang ;

Sharp, Leslie L. ;

Torigian, Drew A. ;

O'Dwyer, Peter J. ;

Vonderheide, Robert H. .

SCIENCE, 2011, 331 (6024) :1612-1616

← 1 2 3 4 5 6 7 8 9 10 →